Navigation Links
Palatin Technologies to Present at Rodman & Renshaw Annual Global Investment Conference
Date:9/10/2010

CRANBURY, N.J., Sept. 10 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced that it will be presenting at the Rodman & Renshaw Annual Global Investment Conference / 12th Annual Healthcare Conference on Tuesday, September 14, 2010 at 10:50 AM ET.  The conference will take place September 12-15 at the New York Palace Hotel in New York, NY.  

Carl Spana, Ph.D., President and Chief Executive Officer of Palatin Technologies, will provide an update on Palatin's corporate and development programs.  A live audio broadcast will be available on the "Investors" section of Palatin's website at www.palatin.com.  The live audio broadcast will be available through September 28, 2010.  

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company dedicated to the development of peptide, peptide mimetic and small molecule agonists with a focus on melanocortin and natriuretic peptide receptor systems. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin Technologies' website at www.palatin.com.

.


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
2. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
3. Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
4. Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America
5. Palatin Technologies to Present at 8th Annual BIO Investor Forum
6. Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men
7. Palatin Technologies, Inc. To Raise $2.6 Million Dollars in Registered Direct Offering
8. Palatin Technologies, Inc. Receives $2.5 Million from AstraZeneca
9. Palatin Technologies, Inc. Announces Positive Safety Results in Subcutaneous Bremelanotide Trial in Men
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... N.J. , July 30, 2015 Eisai ... in the United States , European ... FDA, EMA and MHLW, respectively) for eribulin, for the ... who have received prior chemotherapy for advanced or metastatic ... on data from a pivotal global Phase 3 clinical ...
(Date:7/30/2015)... , July 30, 2015 Takeda Pharmaceutical ... study to fulfill the post-marketing commitment and submissions ... Pan European Multi-Database Bladder Cancer Risk Characterization Study ... cohort study, conducted in four European countries, for ... up to 10 years of follow-up. Findings demonstrate ...
(Date:7/30/2015)... , July 30, 2015  Big Cloud Analytics, ... analytics technology, announces it is working with Intel ... for the new Lockheed Martin Healthcare Technology Alliance. ... health information technology providers, medical technology companies and ... and innovation to improve care in rapidly evolving ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 2Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 3Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 4Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 6Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 2Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 3
... ... Reportlinker.com announces that a new market research report ... Markets for Breast Biopsy Devices 2009 , ... markets for breast biopsy devices includes the spring ...
... , NATICK, Mass. and LONDON, Nov. ... ) today announced that it has received 510(k) clearance ... CE Mark approval to market its WallFlex® Fully Covered ... (obstructions) caused by tumors in patients with resectable or ...
Cached Medicine Technology:Reportlinker Adds Global Markets for Breast Biopsy Devices 2009 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 3Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 4
(Date:7/30/2015)... CA (PRWEB) , ... July 30, 2015 , ... As ... programs, the activity of recruiting patients becomes a serious challenge. Because of growing competition, ... program to patients within the local community. , The team at Wound ...
(Date:7/30/2015)... Angeles, CA (PRWEB) , ... July 30, 2015 , ... The connection between a healthy ... and women. The loss of a full head of hair can have a devastating ... how a person is perceived in the work place, the consequences of hair loss are ...
(Date:7/30/2015)... ... July 30, 2015 , ... Eyepartner is proud to ... San Diego, California’s Gaslamp Quarter Plaza for five years this September. , The ... the area for any suspicious activity. These cameras are in place to provide ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... into one of the largest, family-owned low cost service and repair companies. For ... applications, as well as growing their company to meet the demands of the ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... “Beachside Nursing Center,” to announce its position as one of Medicare’s top-rated ... and staff members support the CMS rating system, which monitors health inspections, ...
Breaking Medicine News(10 mins):Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 4Health News:New Study Shows the Link between Hair Restoration and Healthy Self-Image 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 2Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 3Health News:Beachside Nursing Center Releases New Video 2
... diseases, bringing in hope where ... there is none!, ... resigned to a life of pain with Rheumatoid Arthritis is healthy,and normal ... my,Good Shepherd, Jesus and His own good shepherd, Dr. Omar, have rescued ...
... DCGN ) today announced that it will host ... the Lazard Capital Markets 4th Annual,Healthcare Conference., The ... Tuesday, November,27 at the Palace Hotel, New York City. ... deCODE,s website, http://www.decode.com, and those,interested in listening ...
... Contaminated water could boost child,s cancer risk, study finds ... women exposed to arsenic-contaminated water during pregnancy have gene ... diseases later in life, a Massachusetts Institute of Technology ... work is the first documentation of widespread genetic ...
... AIDS Treatment Provision on World AIDS ... ... to an,increasing need for more effective AIDS treatments in India and recent,high-profile ... Organization (NACO) and Health Minister A.,Ramadoss will announce the rollout of lifesaving ...
... individual has on receiving his paycheque depend critically on ... comes from an experiment conducted by economists and brain ... subjects in pairs, asking them to perform a simple ... tomographs, the researchers examined the volunteers, brain activity throughout ...
... also encourages midday sleepiness, experts say, , , THURSDAY, Nov. ... heads after the Thanksgiving feast aren,t rare, and experts ... during the holiday. , It may have to do ... in tryptophan -- a chemical known to promote sleepiness, ...
Cached Medicine News:Health News:Stem Cells- Dr. Omar Gonzalez' Therapy for all Ills! 2Health News:NACO Bows to Activists' Pressure on AIDS Treatment in India, Says AHF 2Health News:NACO Bows to Activists' Pressure on AIDS Treatment in India, Says AHF 3Health News:Money motivates -- especially when your colleague gets less 2Health News:Money motivates -- especially when your colleague gets less 3Health News:There's More Than Turkey Behind Holiday Yawns 2
... No need to add individual components ... range of trauma indications. Made of an ... than conventional fixators, only much lighter. This ... apply, and more comfortable for the patient. ...
... an X-ray contrast medium for ... for: angiography, urography, phlebography and ... of the basal cisterns, following ... cholangio (pancreato) graphy (ERC(P)), herniography, ...
... (gadobenate dimeglumine) is a paramagnetic MRI contrast ... with gadobenate, a chelating agent that forms ... godolinium ion. It is salified with meglumine ... with all the physico-chemical features typical of ...
... ferumoxides) is Advanced Magnetics' contrast agent for use ... It is the first organ-specific MRI contrast agent ... function, the agent is taken up by macrophages ... in most tumors. The liver is a principal ...
Medicine Products: